Sunesis Pharmaceuticals Announces Third Quarter Teleconference and Webcast on November 4, 2008
SOUTH SAN FRANCISCO, Calif., Oct 28, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS), a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics, today announced that management will webcast a teleconference to review third quarter progress and provide a general business update on Tuesday, November 4, 2008, at 11:00 a.m. ET / 8:00 a.m. PT.
Individual and institutional investors can access the call via 1-877-627-6566 (U.S. and Canada) or +1-719-325-4901 (international). To access the live audio webcast or the subsequent archived recording, visit the "Investors and Media - Calendar of Events" section of the Sunesis website at http://www.sunesis.com.
About Sunesis Pharmaceuticals
Sunesis is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. Sunesis has built a highly experienced cancer drug development organization committed to advancing its lead product candidate, voreloxin, in multiple indications to improve the lives of people with cancer. For additional information on Sunesis Pharmaceuticals, please visit http://www.sunesis.com.
SUNESIS and the logo are trademarks of Sunesis Pharmaceuticals, Inc. Contact: Sunesis Pharmaceuticals, Inc. Eric Bjerkholt 650-266-3717
SOURCE Sunesis Pharmaceuticals, Inc.
Copyright (C) 2008 PR Newswire. All rights reserved
News Provided by COMTEX